Post-Market Study to Assess iTind Safety in Comparison to UroLift (NCT04757116)
A Post-Market, Prospective, Randomized, Controlled, Multicenter International Study to Assess the Safety of the Temporarily Implanted Nitinol Device (iTind) Compared to the UroLift® System in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH)
🩺 Plain-English Summary (8th-Grade Level)
The study objective is to evaluate the efficacy and safety of the iTind device compared to UroLift.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Arizona — Phoenix, Arizona
Age range: 50 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Mayo Clinic Arizona — Phoenix, Arizona
- Arizona Urology Specialists — Tucson, Arizona
- Urology Associates of Central California — Fresno, California
- Golden State Urology — Sacramento, California
- NorthShore University Health System Research Institute — Evanston, Illinois
- Southeast Louisiana Veterans Health Care System — New Orleans, Louisiana
- Minnesota Urology — Woodbury, Minnesota
- The Urology Center — Omaha, Nebraska
- Pacific West Urology — Las Vegas, Nevada
- Feinstein Institutes for Medical Research / Northwell Health — Syosset, New York
- The Conrad Pearson Clinic — Germantown, Tennessee
- Midtown Urology Associates — Austin, Texas
- Houston Metro Urology — Houston, Texas
- The Urology Place — San Antonio, Texas
- Potomac Urology Center — Alexandria, Virginia
- Chelsea and Westminster Hospital — Isleworth, Middlesex
- Queen Margaret Hospital — Dunfermline,
- Frimley Park Hospital — London,
- Norfolk & Norwich University Hospital — Norwich,
📞 Contact the Study Coordinator
Phone: (703) 851-4615
Email: Melanie.Bonds@olympus.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Benign Prostatic Hyperplasia (BPH)
- The FLOW Registry. — Chicago, Illinois
- Evaluation of the Optilume BPH Catheter System and the Rezum Water Vapor Therapy in Treating Benign Prostatic Hyperplasia — Montreal, Quebec
- Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia — Cleveland, Ohio
- Effects of TNF Blockade on Human BPH/LUTS — Glenview, Illinois
Explore by condition: All Benign Prostatic Hyperplasia (BPH) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.